Dr. Ryan Moy
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Area of expertise
Colorectal Cancer
Ryan Moy has run 5 trials for Colorectal Cancer. Some of their research focus areas include:
Cancer
Ryan Moy has run 3 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center
Clinical Trials Ryan Moy is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
Recruiting
2 awards
Phase 3
2 criteria
BMS-986340 + Nivolumab/Docetaxel
for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Recruiting
1 award
Phase 1 & 2
6 criteria
More about Ryan Moy
Clinical Trial Related
3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Ryan Moy has experience with
- 9-ING-41
- BMS-936558-01
- BMS-986340
- Docetaxel
- BAY 1895344
- Fluorouracil
Breakdown of trials Ryan Moy has run
Colorectal Cancer
Cancer
Pancreatic Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ryan Moy specialize in?
Ryan Moy focuses on Colorectal Cancer and Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Mismatch Repair Deficiency positive.
Is Ryan Moy currently recruiting for clinical trials?
Yes, Ryan Moy is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Ryan Moy has studied deeply?
Yes, Ryan Moy has studied treatments such as 9-ING-41, BMS-936558-01, BMS-986340.
What is the best way to schedule an appointment with Ryan Moy?
Apply for one of the trials that Ryan Moy is conducting.
What is the office address of Ryan Moy?
The office of Ryan Moy is located at: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York 10032 United States. This is the address for their practice at the NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.